709 related articles for article (PubMed ID: 25904241)
41. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Golino P
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
[TBL] [Abstract][Full Text] [Related]
42. Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response.
Good RI; McGarrity A; James TE; Miller H; McConnachie A; Goodall AH; Oldroyd KG
Thromb Res; 2015 Jun; 135(6):1140-6. PubMed ID: 25746368
[TBL] [Abstract][Full Text] [Related]
43. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
44. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
45. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD.
Müller KA; Chatterjee M; Rath D; Geisler T
Thromb Haemost; 2015 Aug; 114(3):498-518. PubMed ID: 26224127
[TBL] [Abstract][Full Text] [Related]
46. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
Khanna V; Armstrong PC; Warner TD; Curzen N
Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
[TBL] [Abstract][Full Text] [Related]
47. P2Y
Hensch NR; Karim ZA; Pineda J; Mercado N; Alshbool FZ; Khasawneh FT
Biochem Biophys Res Commun; 2017 Nov; 493(2):1069-1074. PubMed ID: 28928091
[TBL] [Abstract][Full Text] [Related]
48. Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines?
Cayla G; Collet JP; Silvain J; Montalescot G
Arch Cardiovasc Dis; 2014 Jan; 107(1):1-3. PubMed ID: 24332911
[No Abstract] [Full Text] [Related]
49. Antiinflammatory effects of aspirin in ACS: relevant to its cardiocoronary actions?
Hohlfeld T; Schrör K
Thromb Haemost; 2015 Aug; 114(3):469-77. PubMed ID: 26085050
[TBL] [Abstract][Full Text] [Related]
50. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein.
Badrnya S; Butler LM; Söderberg-Naucler C; Volf I; Assinger A
Thromb Haemost; 2012 Oct; 108(4):719-29. PubMed ID: 22836389
[TBL] [Abstract][Full Text] [Related]
51. Modern antiplatelet agents in coronary artery disease.
Power RF; Hynes BG; Moran D; Yagoub H; Kiernan G; Ruggiero NJ; Kiernan TJ
Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1261-72. PubMed ID: 23190065
[TBL] [Abstract][Full Text] [Related]
52. Differential effects of platelets and platelet inhibition by ticagrelor on TLR2- and TLR4-mediated inflammatory responses.
Tunjungputri RN; van der Ven AJ; Riksen N; Rongen G; Tacke S; van den Berg TN; Fijnheer R; Gomes ME; Dinarello CA; van de Veerdonk FL; Gasem MH; Netea MG; Joosten LA; de Groot PG; de Mast Q
Thromb Haemost; 2015 May; 113(5):1035-45. PubMed ID: 25716539
[TBL] [Abstract][Full Text] [Related]
53. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
[TBL] [Abstract][Full Text] [Related]
54. Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory.
Liu L; Li J; Zhang Y; Zhang S; Ye J; Wen Z; Ding J; Kunapuli SP; Luo X; Ding Z
Thromb Res; 2014 Oct; 134(4):866-76. PubMed ID: 25077998
[TBL] [Abstract][Full Text] [Related]
55. P2Y12 receptors: structure and function.
Cattaneo M
J Thromb Haemost; 2015 Jun; 13 Suppl 1():S10-6. PubMed ID: 26149010
[TBL] [Abstract][Full Text] [Related]
56. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.
Tantry US; Bonello L; Aradi D; Price MJ; Jeong YH; Angiolillo DJ; Stone GW; Curzen N; Geisler T; Ten Berg J; Kirtane A; Siller-Matula J; Mahla E; Becker RC; Bhatt DL; Waksman R; Rao SV; Alexopoulos D; Marcucci R; Reny JL; Trenk D; Sibbing D; Gurbel PA;
J Am Coll Cardiol; 2013 Dec; 62(24):2261-73. PubMed ID: 24076493
[TBL] [Abstract][Full Text] [Related]
57. Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines.
Nylander S; Schulz R
Br J Pharmacol; 2016 Apr; 173(7):1163-78. PubMed ID: 26758983
[TBL] [Abstract][Full Text] [Related]
58. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients.
Muhlestein JB
Thromb Haemost; 2010 Jan; 103(1):71-82. PubMed ID: 20062914
[TBL] [Abstract][Full Text] [Related]
59. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel.
Ueno M; Ferreiro JL; Tomasello SD; Tello-Montoliu A; Capodanno D; Seecheran N; Kodali M; Dharmashankar K; Desai B; Charlton RK; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2011 Aug; 4(8):905-12. PubMed ID: 21851906
[TBL] [Abstract][Full Text] [Related]
60. [The role of direct-acting P2Y12 inhibitors in acute coronary syndrome].
Buriakina TA; Zateĭshchikov DA
Kardiologiia; 2012; 52(4):74-9. PubMed ID: 22839520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
